ELECTRONIC LETTER

No correlation between phenotype and genotype in boys with a truncating *MECP2* mutation

K Ravn, J B Nielsen, P Uldall, F J Hansen, M Schwartz

J Med Genet 2003;40:e5(<http://www.jmedgenet.com/cgi/content/full/40/1/e5>)

Rett syndrome (RS, MIM 312750) is an X linked dominant neurodevelopmental disorder, which has been considered to affect girls only.¹ Males were thought to be aborted spontaneously or to have a different phenotype.²

The disease is caused by mutations in *MECP2*, encoding a methyl-CpG binding protein MeCP2.³ MeCP2 is an abundantly expressed protein acting as a global transcription repressor.⁴ The protein contains two domains, the 85 amino acid methyl-CpG binding domain (MBD) and the 102 amino acid transcriptional repression domain (TRD).^{4,5} Furthermore, a domain in the C terminal part of the protein, facilitating DNA binding and harbouring the nuclear localising signal (NLS), has been described.⁶

The mutation responsible for RS has now been found in the majority of RS patients and more than 100 different mutations have been published. Although some association between phenotype and genotype has been shown, their correlation is not predictive of the clinical manifestations in the individual case.^{7,8}

Since 1999, when mutations in *MECP2* were first reported in patients with RS,³ it has been possible to analyse boys for mutations resulting in a confirmation of the diagnosis in some of the earlier reported cases.^{9,10}

Screening of groups of patients with mental retardation of different types has further identified *MECP2* mutations in males. So far, 17 cases of males with a disease causing mutation in *MECP2* have been found. However, six of them were found to have Klinefelter syndrome or were mosaics for the mutation in question.⁸⁻¹⁵ The latter can roughly be divided into two groups, the severe neonatal cases, who die within the first years of life, all caused by an *MECP2* mutation that in females causes classical RS,⁸⁻¹⁰ and the non-specific mental retardation type with mutations that, if present in females, is compatible with normal or mildly retarded development.¹⁶⁻¹⁹

Here we report an 11 year old boy with classical RS, a normal karyotype, no signs of mosaicism, and a de novo truncating mutation (816dup7) in the *MECP2* region encoding the transcriptional repression domain, TRD, in MeCP2.

CASE REPORT

The patient was born at term after a normal pregnancy as the only child of a 24 year old woman and a non-consanguineous, 36 year old man. There are two healthy paternal half sisters. The delivery was by vacuum extraction because of signs of asphyxia. Apgar scores were 7 at one minute and 9 at five minutes, birth weight 2950 g, length 50 cm, and head circumference 37 cm.

He was breast fed for the first months, but was slow to suck. After the shift to formula feeds, he vomited profusely daily and from then on suffered from failure to thrive and retarded growth.

Contact and motor development were considered normal for the first 6 to 7 months. However, he did not sit unsupported before 10 months of age and he never crawled. He used his hands for finger feeding and was able to hold a spoon. He

Key points

- Rett syndrome (RS) used to be considered as affecting girls only. However, 17 males with a mutation in *MECP2* have been reported so far. Six of these had the karyotype 47,XXY or were mosaics for the mutation. The remaining cases can be divided into two groups, a severe type, who die within the first years of life, all caused by an *MECP2* mutation that in females has been found to be associated with classical RS, and a mental retardation type with mutations that, if present in females, are compatible with a normal or mildly retarded development.
- Here we report an 11 year old boy with classical RS, with a normal karyotype, no signs of mosaicism, and a truncating mutation (816dup7) in the *MECP2* region encoding the transcription repression domain, TRD.
- While the genotype-phenotype correlation in females with mutations in *MECP2* is hampered by X chromosome inactivation, the phenotype of males hemizygous for the same mutations should shed light on the effect of these mutations on the phenotype.
- Our patient harbours a typical RS mutation, but unusually has survived beyond early childhood. The hypothesis that other genes are interfering with the clinical features of RS is possible.

babbled at 5-6 months of age, but never spoke words. Around 1 year of age he lost his babbling sounds and the ability to feed himself, and at 15 months of age he was generally retarded. He has never had the typical stereotypic hand movements, but around 2 years of age he started rubbing his eyes stereotypically.

At 2 years seizures during sleep were observed, the EEC was abnormal, and antiepileptic treatment was started, but with limited effect.

Except for an increased ratio of lactate to pyruvate in the spinal fluid all investigations, including a muscle biopsy, were normal. He has a normal male karyotype.

At 10 years old, his height is around 115 cm, weight is 24 kg, and he is microcephalic with a head circumference of 47.2 cm. He can sit unsupported, walk a few steps with good support, hold a cup, and drink with some help. He can make intense eye contact, but he seldom smiles and often has an anguished look. He rubs his eyes intensively and his eye surroundings are red and swollen. He is ataxic and spastic; he grinds his teeth, has a high pain threshold, and is often constipated. He has a severe thoracolumbar scoliosis with pronounced rotation. For the last two years he has been seizure free without treatment.

The intense eye contact raised the suspicion of RS and a mutation screen of *MECP2* was performed. He fulfils all the necessary and some of the supportive criteria for RS.²⁰

Figure 1 Sequence of the part of the *MECP2* gene showing the 7 bp duplication. The duplication is underlined.

MATERIAL AND METHODS

Total genomic DNA was extracted from peripheral blood leucocytes, fibroblasts, hair roots, a skeletal muscle biopsy, and buccal cells according to standard procedures.

Mutation detection

PCR amplification of a 174 bp segment containing exon 2 and a 2430 bp segment containing exon 3, intron 3, and exon 4 of *MECP2* was performed using the following primers 5'-GTTATGCTTTAGTCTTGG-3' (forward), 5'-TGTGTTTATCTTCAAATGT-3' (reverse) and 5'-CCTGCCTCTGCTCACTTGT-3' (forward), 5'-CGGTAAGAAAAACATCCCCAA-3' (reverse) and Expand™ Long Template PCR System (Boehringer Mannheim).

After purification the PCR products were analysed by direct sequencing using an ABI 310 automated DNA sequencer and fluorescent dye labelled ddNTP chain terminators (Big-dye Sequencing System, PE-Biosystems) according to the manufacturer's specifications. The sequencing primers used in this work correspond to the forward primers published by Amir *et al.*³

Detection of 816dup7

For direct detection of 816dup 7, PCR amplification was performed with the following primers: 5'-Fam-GGCAGGAAGCGAAAAGCTGAG-3' (forward) and 5'-CTGCACAGATCGGATAAGAAGAC-3' (reverse). The sizes of the normal and the 816dup7 alleles were 135 bp and 142 bp, respectively. The PCR products were analysed on an ABI-310 using the Genescan software (PE-Biosystems).

Allele specific detection of wild type *MECP2* allele

We designed a specific primer 5'-AAGAAACGGGGCCG**AAAGCCGGGG**-3' (forward) (bold letters indicate the sequence and position which is duplicated in the mutated allele), which in combination with a reverse primer 5'-TGAGTGGTGGTATGGTGGTGG-3' amplifies a 324 bp PCR product only when a normal allele is present.

To study the sensitivity of the amplification, two PCR products of 617 bp (nt 756-1372) covering the normal and the mutated allele, respectively, were cloned into two pGEM-T cloning vectors (Promega, Madison, WI) according to the manufacturer's instructions. A serial dilution of a mixture of normal and mutant purified plasmid DNA, containing a ratio of normal to mutant DNA of 1:1 down to 1:100 000, was performed. PCR using the primer set described above was performed and the products analysed on an agarose gel.

Analysis of the *MECP2* mRNA level

For RT-PCR analyses, total RNA was extracted from cultured fibroblast cell lines using RNeasy kit (Qiagen). cDNA was

Figure 2 Fragment analysis for the 7 bp duplication. Arrows indicate the normal allele of 135 bases and the mutated one of 142 bases. The peaks from the GeneScan™ - 500 Rox™ size standard are also shown. Panel 1: DNA from the patient's mother. Panels 2, 3, 4, 5, and 6: DNA from the patient's fibroblasts, hair roots, leucocytes, muscle, and buccal cells, respectively.

generated by the GeneAmp RNA-PCR kit from Perkin Elmer with MuLV reverse transcriptase and random hexamers as primers. Amplification of a 264 bp PCR product of the *MECP2* cDNA was performed using intron spanning primers 5'-Hex-AGCCCGTGCAGCCATCAGCC-3' (in exon 3) and 5'-GAGAAAGGCTTTCCCTGGG-3' (exon 4). Simultaneously, a 111 bp PCR product was amplified from the *GAPDH* cDNA using the primers 5'-Hex-TGGGGAAGGTGAAGGTCGA-3' (forward) and 5'-GAAGGGGTCATTGATGGCAA-3' (reverse) spanning the splice site of *GAPDH* exon 1 and exon 2. The PCR products were analysed on an ABI-310 using the Genescan software (PE-Biosystems) and the ratio of the area of the peaks of *MECP2* and *GAPDH* PCR products were calculated and used for semiquantitative determination of the expression level of the *MECP2* mRNA.

RESULTS

Direct sequencing of the three coding exons and flanking intron sequences of the *MECP2* identified a duplication of 7 bp (AAAGCCG) at position 816 in the transcriptional repression domain (TRD), which is located in exon 4 (fig 1). The patient's mother did not harbour the mutation.

In order to test for possible mosaicism, we investigated DNA from several different tissues, including fibroblasts, hair roots, leucocytes, muscle, and buccal cells. The single appearance of the 142 bp peak in each DNA sample indicated the existence of only the mutant allele (fig 2, lanes 2 to 6).

Figure 3 Allele specific PCR for the normal allele. Lane 1: molecular weight marker. Lane 2: PCR amplification of 100 000 normal *MECP2* alleles. Lane 3: PCR amplification of 200 normal *MECP2* alleles among 100 000 mutant alleles. In this dilution, the normal allele is still detectable.

To exclude any preferential amplification of the mutant allele, we designed an allele specific primer system, which shows a PCR product only if the normal allele is present. The system was able to detect fewer than 200 normal alleles among 100 000 mutant alleles (fig 3). The assay showed no sign of mosaicism in any of the tissues studied, which represent all three germ layers, the ectoderm, mesoderm, and endoderm, strongly suggesting that our patient is truly hemizygous for 816dup7.

We determined the ratio between the level of *MECP2* mRNA and *GAPDH* mRNA in cultivated fibroblasts from the patient and from five control cell lines. Our results showed that the expression of the 816dup7 allele appeared to be equal to that of the normal allele in five control fibroblast cell lines.

DISCUSSION

RS is an X linked disease almost affecting girls only, while male fetuses are believed to be aborted spontaneously. After the identification of *MECP2* as the gene responsible for RS, mutations have been identified in the majority of RS patients. Mutations have been found in all parts of the gene, but some mutations seem to be recurrent. No clear correlation between genotype and phenotype has been established, although some

reports^{7 8} seem to indicate that patients with MBD mutations (both missense and truncating) show a more severe clinical presentation than patients with missense and nonsense mutations further downstream in the gene. Mutation studies have shown *MECP2* mutations in males with different clinical features, ranging from severe neonatal encephalopathy and death to mild mental retardation. The “male” *MECP2* mutations reported so far can be divided into two groups (table 1): mutations which are known or strongly suspected to cause RS, when present in girls, and mutations which apparently do not affect the female phenotype or cause mild mental retardation. So far 10 patients, including our own, have been identified in the first group. These mutations are either frameshift or nonsense mutations, believed to result in the expression of a truncated protein, or the recurrent T158M and R133H mutations, which are some of the most common mutations in RS patients. Six of these nine patients fulfil all the criteria for RS. However, these patients are either mosaics for the mutation in question or have a 47,XXY karyotype and are thus not hemizygous for the mutation. Three of the nine patients died very early, because of severe neonatal encephalopathy, and thus did not have an RS phenotype. These results strongly support the idea that true RS mutations are lethal or cause very early death in hemizygous males. However, our patient is an exception as he is now 11 years old and fulfils the criteria for RS.

We investigated several tissues from our patient, representing the endoderm (buccal cells), ectoderm (hair roots), and the mesoderm (leucocytes, fibroblasts, and muscle), in order to detect any possible mosaicism. The assay will detect a normal allele if present down to a ratio between normal and mutant alleles of 1:200. We did not find any signs of mosaicism. We believe that this patient is a true hemizygous male, but we cannot prove that some non-mutated cells exist in the brain alone. Although the 816dup7 mutation has not been found in females, it is predicted to cause RS, since a large range of this type of frameshift mutations in the region encoding the TRD has been reported in girls with classical RS.

While predicting and comparing the genotype-phenotype correlation in females with mutation in *MECP2* are hampered by X chromosome inactivation, the phenotype of males hemizygous for the same type of mutations should shed light on the pathogenic effect of these mutations. We have compared our patient's mutation and clinical appearance with those of previously reported male patients.

One other *MECP2* mutation found in a male, 806delG,⁹ is comparable to our 816dup7 mutation when the predicted proteins are considered (fig 4). Both mutations cause a

Table 1 Male *MECP2* mutations, their predicted effect on MeCP2, and the observed phenotypes in males and females

Mutation	Type	Domain	Family	Comments	Male phenotype	Female phenotype	Ref
806delG	Truncating	TRD	+		Severe, neonatal, early death	RS	9
1154del32	Truncating	After TRD	+	inv(X)(q27;q28)	Severe, neonatal, early death	RS	8
T158M	Missense	MBD	+		Severe, neonatal, early death	RS	10
T158M	Missense	MBD	–	47,XXY / 46,XY	RS	RS	12
T158M	Missense	MBD	–	47,XXY	RS	RS	13
R270X	Truncating	TRD	–	Mosaic	RS	RS	15
816dup7	Truncating	TRD	–	Probably germline	RS	RS, probably	This report
166del2	Truncating	Before MBD	–	Mosaic	RS-like	RS, probably	11
R133H	Missense	MBD	–	Mosaic	RS-like	RS	14
Y141X	Truncating	MBD	–	47,XXY	RS-like	RS, probably	13
Q406X	Truncating	After TRD	+		MR, progressive spasticity	Normal (random XCI)	17
G428S	Missense	After TRD	+		Non-progressive encephalopathy	Normal (random XCI)	18
A140V	Missense	MBD	+		Non-specific MR	Mild retardation	16
E137G	Missense	MBD	+		Non-specific MR	Normal (random XCI)	19
R167W	Missense	After MBD	+		Non-specific MR	Normal (random XCI)	19
A140V	Missense	MBD	+		Non-specific MR	Normal (random XCI)	19
P399L	Missense	After TRD	?	Polymorphism ?	Non-specific MR	Not known	19
R453Q	Missense	After TRD	?	Polymorphism ?	Non-specific MR	Not known	19

Figure 4 Schematic presentation of the predicted MeCP2 proteins for four MECP2 mutations. The figures indicate the amino acid number. (Above) Normal MeCP2. MBD: methyl binding domain. TRD: transcriptional repression domain. C-ter: C-terminal part of the protein believed to facilitate DNA binding. NLS: Nucleic acid localisation signal. (Below) Solid lines: predicted protein with a correct aa sequence. Broken lines: incorrect aa sequence.

Table 2 Comparison of signs present in female Rett syndrome, in the male with Q406X, and in the male with 816dup7 reported in the present paper

Symptom	Rett syndrome	Q406X	816dup7
Absence of language	+	+	+
Seizures	+	+	+
Spasticity	+	+	+
Atactic gait	+	+	+
Sialorrhoea	+	+	When younger
Grinding of teeth	+	+	+
Microcephaly	+	—	+
Stereotypic hand movements	+	—	(+)*
Growth retardation	+	—	+
Loss of acquired purposeful hand skills	+	—	+
Constipation	+	—	+
Choreoathetotic movements	—	+	—
Facial hypotonia	—	+	—

*He rubs his eyes stereotypically.

frameshift, resulting in a nonsense codon downstream of the mutation. The corresponding mRNAs for both mutations are found in normal amounts and truncated proteins are therefore likely to be produced. The mutations are predicted to result in a truncated protein of 288 and 332 amino acids (aa), respectively. The amino acid sequence of the 816dup7 protein is correct until aa 274, and the putative nuclear localising signal (NLS) (aa 252-271) is therefore maintained, which is only partly the case for the 806delG protein, in which the correct amino acid sequence ends with aa 268. Both proteins will lack the C-terminal part and the domain believed to facilitate DNA binding. The phenotypic difference between these two patients is striking considering the similarity between the genotypes (table 1).

On the other hand, our patient shares several phenotypic signs with the patient reported by Meloni *et al*¹⁷ (table 2), harbouring the Q406X mutation. This patient has some RS features, but lacks some of the major criteria. He is mentally retarded and suffers from progressive spasticity. The Q406X mutation was identified in a family in which two females were heterozygous for the mutation, but presented with normal to borderline intelligence and absence of skewed X inactivation. The mutation is therefore not a classical RS mutation. The Q406X mutation is predicted to produce a protein of 405 aa, with intact TRD and NLS, lacking only part of the C-terminal region of the protein.

The mutation 1154del32⁸ predicts a protein very similar to that of Q406X, but was found in a male suffering from neonatal encephalopathy, who died in early childhood.

The idea that the identification of males with mutations in MECP2 would solve the enigma of the different phenotypes

associated with the mutations is not supported, and it has been suggested that other genes interfere in the development of the clinical features in these patients. MECP2 is not the only gene active in DNA methylation dependent transcriptional repression²¹ and variation/mutations in other genes could therefore explain the lack of genotype-phenotype correlation discussed here. Polymorphisms have been shown to modulate the phenotypic expression of disease mutations in other genes, for example, CFTR,^{22, 23} and very little is known about variation in the introns in MECP2 or the importance of the alternative MECP2 transcripts.

The patient presented here adds to the variation in the phenotypic expression of mutations in MECP2, ranging from severe encephalopathy and neonatal death in classical RS to mild mental retardation found in both females and males.

ACKNOWLEDGEMENTS

This work was supported by grants from the Novo Nordic Foundation, The Gangsted-Rasmussen Foundation, Dagmar Marshall Foundation, and Signe and Peter Gregersen Foundation.

Authors' affiliations

K Ravn, J B Nielsen, M Schwartz, Department of Clinical Genetics, University Hospital, Rigshospitalet, Copenhagen, Denmark

J B Nielsen, The John F Kennedy Institute, Gl Landevej 7, DK-2200 Glostrup, Denmark

P Uldall, F J Hansen, Department of Paediatrics, University Hospital, Rigshospitalet, Copenhagen, Denmark

Correspondence to: Dr M Schwartz, Department of Clinical Genetics, Rigshospitalet 4062, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; schwartz@rh.dk

REFERENCES

- Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. *Ann Neurol* 1983;**14**:471-9.
- Schanen NC, Francke U. A severely affected male born into a Rett syndrome kindred supports X-linked inheritance and allows extension of the exclusion map. *Am J Hum Genet* 1998;**63**:267-9.
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein. *Nat Genet* 1999;**23**:185-8.
- Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. *Cell* 1997;**88**:471-81.
- Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. *Nucleic Acids Res* 1993;**21**:4886-92.
- Chandler SP, Guschin D, Landsberger N, Wolffe AP. The methyl-CpG binding transcriptional repressor MeCP2 stably associates with nucleosomal DNA. *Biochemistry* 1999;**38**:7008-18.
- Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, Leonard H, Krawczak M, Cooper DN, Lynch S, Thomas N, Hughes H, Hulten M, Ravine D, Sampson JR, Clarke A. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. *Hum Mol Genet* 2000;**9**:1119-29.
- Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, Schuette JJ, Marino M, Philippart M, Narayanan V, Umansky R, Kronn D, Hoffman EP, Naidu S. MECP2 mutations in children with and without the phenotype of Rett syndrome. *Neurology* 2001;**56**:1486-95.
- Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, Budden S, Naidu S, Pereira JL, Lo IF, Zoghbi HY, Schanen NC, Francke U. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. *Am J Hum Genet* 1999;**65**:1520-9.
- Villard L, Cardoso AK, Chelly PJ, Tardieu PM, Fontes M. Two affected boys in a Rett syndrome family: clinical and molecular findings. *Neurology* 2000;**55**:1188-93.
- Clayton-Smith J, Watson P, Ramsden S, Black GC. Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. *Lancet* 2000;**356**:830-2.
- Leonard H, Silberstein J, Falk R, Houwink-Manville I, Ellaway C, Raffaele LS, Engerstrom IW, Schanen C. Occurrence of Rett syndrome in boys. *J Child Neurol* 2001;**16**:333-8.
- Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. *Neuropediatrics* 2001;**32**:162-4.
- Armstrong J, Pineda M, Aibar E, Gean E, Monros E. Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation. *Ann Neurol* 2001;**50**:692.
- Topcu M, Akyerli C, Sayi A, Toruner GA, Kocoglu SR, Cimbis M, Ozelik T. Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. *Eur J Hum Genet* 2002;**10**:77-81.

- 16 **Orrico A**, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, Poon PM, Zappella M, Federico A, Sorrentino V. MECP2 mutation in male patients with non-specific X-linked mental retardation. *FEBS Lett* 2000;**481**:285-8.
- 17 **Meloni I**, Bruttini M, Longo I, Mari F, Rizzolio F, D'Adamo P, Devriendt K, Fryns JP, Renieri T. A mutation in the Rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. *Am J Hum Genet* 2000;**67**:982-5.
- 18 **Imessaoudene B**, Bonnefont JP, Royer G, Cormier-Daire V, Lyonnet S, Lyon G, Munnich A, Amiel J. MECP2 mutation in non-fatal, non-progressive encephalopathy in a male. *J Med Genet* 2001;**38**:171-4.
- 19 **Couvert P**, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, Verloes A, Andres C, Le Fevre AC, Souville I, Steffann J, des Portes V, Ropers HH, Yntema HG, Fryns JP, Briault S, Chelly J, Cherif B. MECP2 is highly mutated in X-linked mental retardation. *Hum Mol Genet* 2001;**10**:941-6.
- 20 **The Rett Syndrome Diagnostic Criteria Work Group**. Diagnostic criteria for Rett syndrome. *Ann Neurol* 1988;**23**:425-8.
- 21 **Wade PA**. Methyl CpG-binding proteins and transcriptional repression. *BioEssays* 2001;**23**:1131-7.
- 22 **Kiesewetter S**, Macek M Jr, Davis C, Currstin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsui LC, Mickle J, Amos J, Highsmith WE, Shuber A, Witt DR, Cutting GR. A mutation in CFTR produces different phenotypes depending on chromosomal background. *Nat Genet* 1993;**5**:274-8.
- 23 **Cuppens H**, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogsmans G, Reynaert I, Goossens M, Niius B, Cassiman JJ. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. *J Clin Invest* 1998;**101**:487-96.